[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
D001629:Bezafibrate; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013806:Theophylline / Q000031:analogs & derivatives*; D014971:Xanthinol Niacinate / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; C009746:etofibrate; D002995:Clofibric Acid; D014971:Xanthinol Niacinate; D002784:Cholesterol; D013806:Theophylline; D002994:Clofibrate; D001629:Bezafibrate
Lipidsenkende Wirkung von Etofibrat, Bezafibrat und Xantinol-Nikotinat bei Patienten mit Hyperlipoproteinämien.